Printer Friendly

CURATIVE TECHNOLOGIES, INC. ANNOUNCES THIRD QUARTER RESULTS

 EAST SETAUKET, N.Y., Nov. 2 /PRNewswire/ -- Curative Technologies, Inc. (NASDAQ: CURE) ("CTI") today announced its financial results for the third quarter ended September 30, 1993. Total revenues for the quarter increased 30 percent to $9.7 million, compared with $7.5 million for the same quarter of 1992 and up 11 percent versus the second quarter of 1993. The Company recorded a net loss of $926,000, or $(.09) per share for the quarter, versus a net loss of $749,000, or $(.08) per share for the comparable quarter of 1992 and $1,167,000, or $(.12) per share for the second quarter of 1993.
 Revenues for the nine months of fiscal 1993 were $2.5 million, exceeding revenues of $18.9 million for the first nine months of 1992 by 40 percent. The net loss for the nine months of fiscal 1993 was $3.4 million, or $(.34) per share versus a net loss of $3.1 million, or $(.31) per share for the same period last year.
 "We are very pleased with the growth and progress Curative Technologies, Inc. sustained during the quarter," said Russell B. Whitman, Chairman, President and CEO. The Wound Care business continues to expand with the number of Wound Care Centers(R) open or under contract to open at 56 and the subacute care wound management facilities totaling 3. New patient flow into the Wound Care Center(R) network continues to be strong and was up 37 percent over the prior year.
 The Biopharmaceutical business is also progressing with patient enrollment continuing in pivotal clinical trials of CT-102 for diabetic ulcers in the United States and Europe. During the quarter two articles appeared in the peer reviewed journal Wounds which support both the clinical efficacy as well as the cost efficacy for platelet releasate technology. We also continue to be encouraged by the preclinical research we are conducting with small polypeptides. This effort is focusing on anti-inflammatory indications and CT-112, the lead compound, is showing promising results in this area.
 Curative Technologies, Inc., is a technology driven healthcare company that has established itself as a leader in wound healing by providing a range of specialty products and services to healthcare providers through a nationwide network of Wound Care Centers(R). The Company is also engaged in the research, development, production and marketing of therapeutic products utilizing naturally occurring human growth factors.
 CURATIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
 Selected Financial Information
 Condensed Consolidated Statement of Operations
 (Dollars in thousands, except per share data -- Unaudited)
 Three Months Ended Nine Months Ended
 September 30, September 30,
 1993 1992 1993 1992
 Revenue $ 9,702 $ 7,484 $26,464 $18,887
 Cost and expenses:
 Cost of product sales
 and services 5,295 3,648 14,168 9,604
 Research and development 1,847 1,894 5,656 4,840
 Selling, general &
 administrative 3,671 3,059 10,689 8,431
 Total costs and expenses 10,813 8,601 30,513 22,875
 Loss from operations (1,111) (1,117) (4,049) (3,988)
 Interest income 130 317 449 812
 Net loss before minority
 interest (981) (800) (3,600) (3,176)
 Minority interest in net loss
 of consolidated subsidiary 55 51 198 109
 Net loss $ (926) $ (749) $(3,402) $(3,067)
 Net loss per common share $ (.09) $ (.08) $ (.34) $ (.31)
 Weighted average common
 shares outstanding 9,903 9,892 9,903 9,887
 Condensed Consolidated Balance Sheet
 (Dollars in thousands -- Unaudited)
 September 30, 1993 December 31, 1992
 Asset
 Cash and cash equivalents $ 1,723 $ 736
 Marketable securities 9,284 17,773
 Other current assets 11,080 6,983
 Property and equipment (net) 3,410 2,636
 Other assets 969 946
 $ 26,466 $ 29,074
 Liabilities and Stockholders' Equity
 Current liabilities $ 8,107 $ 6,364
 Long-term debt 270 202
 Other liabilities 242 1,069
 Stockholders' equity 17,847 21,439
 $ 26,466 $ 29,074
 -0- 11/2/93
 /CONTACT: John C. Prior, chief financial officer of Curative Technologies, Inc., 516-689-7000, or Anthony J. Russo, Ph.D., or Rhonda Chiger of Noonan/Russo Communications Inc., 212-696-4455/
 (CURE)


CO: Curative Technologies, Inc. ST: New York IN: MTC SU: ERN

SH-TW -- NY014 -- 9521 11/02/93 09:13 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 2, 1993
Words:695
Previous Article:HOLOPAK TECHNOLOGIES, INC. ANNOUNCES 302 PERCENT INCREASE IN NET INCOME ON 80 PERCENT INCREASE IN SALES
Next Article:PITTWAY'S THIRD QUARTER INCOME FROM CONTINUING OPERATIONS UP 44 PERCENT ON 15 PERCENT SALES INCREASE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters